Analyst Ratings For Omega Diagnostics Group Plc (LON:ODX)
Today, FinnCap reiterated its Corporate rating on Omega Diagnostics Group Plc (LON:ODX) with a price target of GBX 28.
There are no ratings tracked in the last 12 months. on the stock.
The current consensus rating on Omega Diagnostics Group Plc (LON:ODX) is N/A (Score: NaN) with a consensus target price of GBX 28 per share, a potential .
Some recent analyst ratings include
- 2/24/2017-FinnCap Reiterated Rating of Corporate.
About Omega Diagnostics Group Plc (LON:ODX)
Omega Diagnostics Group PLC is a medical diagnostics company. The Company’s segments are Allergy and Autoimmune; Food Intolerance; Infectious/Other, and Corporate. Its product categories include allergy, anemia, autoimmunity, fertility and growth hormones, food intolerance, infectious disease, inflammation, quality control, thyroid hormones and tumor markers. For allergy, it offers Allergodip, which is an enzyme immunoassay for the semi-quantitative determination of Specific immunoglobulin E (IgE) in serum or plasma. For anemia, it offers ATHOZYME Ferritin, which is an enzyme-immunoassay (ELISA) test for the detection and quantification of Ferritin in human serum. It offers a range of products for Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Antiphospholipid Syndrome (APS), Connective Tissue Disease, Gastrointestinal, and Vasculitis and Renal Disease. Its Fertility Hormones products include PATHOZYME-LH (Luteinizing Hormone), PATHOZYME-Prolactin and PATHOZYME-Oestradiol.
Recent Trading Activity for Omega Diagnostics Group Plc (LON:ODX)
Shares of Omega Diagnostics Group Plc closed the previous trading session at 18.58 up +0.33 1.79% with 0 shares trading hands.
